Assays for predicting and monitoring responses to lung cancer immunotherapy.
about
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysisThe promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies.Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix.Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer.Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma.Erratum to Assays for predicting and monitoring responses to lung cancer immunotherapy.Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy.Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy.
P2860
Q26741101-97C4916A-F678-495B-B795-CAB966C5C26DQ26769728-0399E7A2-E4F0-4B57-8733-746561515694Q28069924-A4F7A289-5707-425C-8532-96E0A8C2133CQ36994508-D94931AA-E080-4813-86F2-30795EDA2CC3Q37061685-00FBF131-E825-45B9-99B2-AE49115F7562Q37094056-63F1041C-863C-4BAA-A3AF-FC4880531BD2Q37688658-6092AAE4-3D34-4F98-BF19-B40D00D2CA36Q38796541-0B48BD54-90B4-4B0E-86FB-312DDA70EB05Q41145904-A9D4E6F9-1162-4F3D-9108-2937A7D339D0Q43217644-D4A10703-65C1-4E63-B688-939190CADC0BQ47164059-8D47D516-E99A-4714-AB0D-4A32BD4D6C6AQ49723499-8AF1AAAE-2E22-48D3-B354-C5BE848F6542Q54963997-C0C584A8-140E-4BA8-86C7-DD3B070FABAA
P2860
Assays for predicting and monitoring responses to lung cancer immunotherapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Assays for predicting and monitoring responses to lung cancer immunotherapy.
@en
type
label
Assays for predicting and monitoring responses to lung cancer immunotherapy.
@en
prefLabel
Assays for predicting and monitoring responses to lung cancer immunotherapy.
@en
P2093
P2860
P1476
Assays for predicting and monitoring responses to lung cancer immunotherapy.
@en
P2093
Cristina Teixidó
Daniela Morales-Espinosa
Maria González-Cao
Niki Karachaliou
P2860
P356
10.7497/J.ISSN.2095-3941.2015.0019
P577
2015-06-01T00:00:00Z